Depletion in LpA-I:A-II particles enhances HDL-mediated endothelial protection in familial LCAT deficiency

Area of Science:

• Cardiovascular Science
• Lipid Metabolism
• Endothelial Biology

Background:

• Lecithin-cholesterol acyltransferase (LCAT) deficiency is characterized by altered high-density lipoprotein (HDL) composition, specifically reduced LpA-I:A-II particles.
• HDL functionality is crucial for vascular health, influencing processes like nitric oxide (NO) production and endothelial cell activation.

Purpose of the Study:

• To evaluate the vasoprotective effects of HDL isolated from carriers of LCAT deficiency.
• To investigate the impact of altered HDL composition on endothelial nitric oxide synthase (eNOS) activation and vascular cell adhesion molecule-1 (VCAM-1) expression.

Main Methods:

• Isolated HDL from LCAT-deficient carriers and control individuals.
• Assessed HDL's capacity to promote NO production in cultured endothelial cells.
• Measured inhibition of vascular cell adhesion molecule-1 (VCAM-1) expression by HDL in vitro.

Main Results:

• HDL from LCAT deficiency carriers significantly increased eNOS activation and NO production compared to control HDL.
• HDL from carriers demonstrated a greater inhibition of VCAM-1 expression in endothelial cells.
• These effects showed a gene-dose-dependent relationship and were linked to the depletion of LpA-I:A-II particles.

Conclusions:

• Selective depletion of apoA-II-containing HDL in LCAT deficiency enhances HDL's ability to stimulate endothelial NO production.
• Altered HDL apolipoprotein composition, rather than just HDL-cholesterol levels, significantly impacts HDL's vasoprotective functions.
• Targeting HDL apolipoprotein composition represents a potential therapeutic strategy for improving cardiovascular health.